Home1RGEN • BIT
add
Repligen Corp
Previous close
€116.00
Year range
€96.26 - €156.25
Market cap
7.25B USD
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 197.91M | 18.12% |
Operating expense | 83.46M | 68.27% |
Net income | 13.29M | 139.23% |
Net profit margin | 6.71 | 133.20% |
Earnings per share | 0.49 | 11.36% |
EBITDA | 39.92M | -18.67% |
Effective tax rate | 30.48% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 767.63M | 1.36% |
Total assets | 2.95B | 4.24% |
Total liabilities | 843.57M | -1.56% |
Total equity | 2.11B | — |
Shares outstanding | 56.33M | — |
Price to book | 3.10 | — |
Return on assets | 1.70% | — |
Return on capital | 1.79% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | 13.29M | 139.23% |
Cash from operations | 25.70M | -34.39% |
Cash from investing | -208.74M | -222.32% |
Cash from financing | 195.00K | -86.54% |
Net change in cash | -182.73M | -586.71% |
Free cash flow | 9.78M | -89.46% |
About
Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The company is based in Waltham, Massachusetts, and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations worldwide. Wikipedia
CEO
Founded
1981
Headquarters
Website
Employees
2,000
